Praeventix is a biopharmaceutical company dedicated to developing innovative therapies targeting serotonergic-driven disorders. The company is primarily focused on the research and early clinical development of 5-HT7 receptor antagonists, with its lead candidate, PRA-523, being positioned as a potential first-in-class treatment for chronic pruritus, inflammatory bowel disease (IBD), and cocaine use disorder (CUD). The therapeutic approach is based on the understanding that serotonin (5-HT) plays a significant role in the severity of pruritus, particularly in conditions like atopic dermatitis, where elevated levels of serotonin have been observed. By selectively blocking 5-HT7 receptor activation, Praeventix aims to provide effective management for pruritus, which is a common and distressing symptom affecting a substantial portion of the population.

In addition to its focus on chronic pruritus, Praeventix is exploring the potential of its serotonergic therapeutics in treating IBD, a condition affecting millions of Americans with chronic gastrointestinal inflammation, and CUD, which has significant implications for the reward system in the brain. The company’s commitment to addressing unmet medical needs in these areas is underscored by its experienced leadership team, which includes individuals with extensive backgrounds in drug development and commercialization. Through its innovative research and development efforts, Praeventix aims to improve the quality of life for patients suffering from these challenging disorders.

United States

Praeventix is an early development stage biopharmaceutical company committed to the discovery, research and early clinical development of novel serotonergic compounds for the treatment of gastrointestinal diseases.

Praeventix

Company Details